Gastrointestinal stromal tumor

Abstract

Background: GISTs are a subset of mesenchymal tumors and represent the most common mesenchymal neoplasms of GI tract. However, GIST is a recently recognized tumor entity and the literature on these stromal tumors has rapidly expanded.

Expression of DOG1, CD117 and PDGFRA in Gastrointestinal Stromal Tumors and Correlations with Clinicopathology

“…According to foreign reports, the incidence of GISTs is 1-2/100, 000, under 3% of total gastrointestinal tumors, however, GISTs is the most common mesenchymal tumors of the digestive tract. It can appeared anywhere of the digestive tract, most commonly in stomach (60%-70%), small intestine (20%-30%), or rectum and colon(5%), esophagus fewer than 5%, and sometimes in omentum and mesenterium (Miettinen et al, 2005;Dow et al, 2006;Stamatakos et al, 2009). The age peak of incidence is 55-65, male slightly higher than female or almost equal for both sexes (Bórquez Ma et al, 2008;Corless et al, 2008).…”

Low ING4 protein expression detected by paraffin-section immunohistochemistry is associated with poor prognosis in untreated patients with gastrointestinal stromal tumors

“…in the colorectum (5-10 %) and esophagus (0-5 %), with rare cases in mesentery, omentum, and retroperitoneum [1,7]. Up to now, the prognosis of GISTs has relied clinically on tumor size, mitosis, and location, but exceptions exist.…”

Treatment of refractory gastrointestinal stromal tumor using pazopanib

“…Its incidence rate is 1-1.5 per 100,000 per year (1), consistent to the worldwide incidence of approximately 10-20 million people per year (2). Although GIST is generally resistant to both radiation therapy and chemotherapy, over the last two decades GIST has become one of the most controllable sarcoma by molecularly targeted therapies (3).…”